|
|
Vaccine Detail
|
PSA/PSMA DNA Plasmid INO-5150 Vaccine |
| Vaccine Information |
- Vaccine Name: PSA/PSMA DNA Plasmid INO-5150 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007154
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- FOLH1
gene engineering:
- Type: Recombinant protein preparation
- Description: (Shore et al., 2020)
- Detailed Gene Information: Click Here.
- Description: This is for Prostate Cancer (NCT02514213). A plasmid DNA vaccine encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery and electroporation of the PSA/PSMA DNA plasmid INO-5150, both PSA and PSMA are translated in cells which then activate the immune system. This induces cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing PSA and PSMA. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. PSA and PSMA are overexpressed on a variety of cancer cell types. The DNA encoding the TAAs in INO-5150 is based on both human and other primate antigen gene sequences. As the plasmid genes differ from the human gene sequences encoding these antigens, INO-5150 may overcome immune tolerance to human TAAs (Shore et al., 2020; NCIT_C123283).
|
| Host Response |
|
|
| References |
NCIT_C123283: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C123283]
NCT02514213: [https://clinicaltrials.gov/show/NCT02514213]
Shore et al., 2020: Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, Appleman LJ, Tutrone R, Garcia JA, Whang YE, Kelly WK, Weiner DB, Bagarazzi ML, Skolnik JM. CD8(+) T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Molecular therapy : the journal of the American Society of Gene Therapy. 2020; 28(5); 1238-1250. [PubMed: 32208168].
|
|
